You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

Desvenlafaxine - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for desvenlafaxine and what is the scope of patent protection?

Desvenlafaxine is the generic ingredient in four branded drugs marketed by Alembic Pharms Ltd, Osmotica Pharm Corp, Sun Pharm, Teva Pharms Usa, Actavis Labs Fl, Alembic, Hikma, Intellipharmaceutics, Lupin Ltd, Norvium Bioscience, Rubicon, Yichang Humanwell, Zydus Pharms, and Pf Prism Cv, and is included in fifteen NDAs. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

There are sixteen drug master file entries for desvenlafaxine. Two suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for desvenlafaxine
Drug Prices for desvenlafaxine

See drug prices for desvenlafaxine

Recent Clinical Trials for desvenlafaxine

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da SaudePhase 2
Sage TherapeuticsPhase 3
H. Lundbeck A/SPhase 4

See all desvenlafaxine clinical trials

Generic filers with tentative approvals for DESVENLAFAXINE
Applicant Application No. Strength Dosage Form
⤷  Sign Up⤷  Sign Up100MGTABLET, EXTENDED RELEASE;ORAL
⤷  Sign Up⤷  Sign Up50MGTABLET, EXTENDED RELEASE;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Anatomical Therapeutic Chemical (ATC) Classes for desvenlafaxine

US Patents and Regulatory Information for desvenlafaxine

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Actavis Labs Fl DESVENLAFAXINE SUCCINATE desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 204065-002 Jul 29, 2016 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Actavis Labs Fl DESVENLAFAXINE SUCCINATE desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 204065-001 Jul 29, 2016 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Sun Pharm DESVENLAFAXINE desvenlafaxine fumarate TABLET, EXTENDED RELEASE;ORAL 205583-002 Jan 28, 2014 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Teva Pharms Usa DESVENLAFAXINE desvenlafaxine fumarate TABLET, EXTENDED RELEASE;ORAL 205208-002 Oct 11, 2013 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Alembic Pharms Ltd DESVENLAFAXINE desvenlafaxine TABLET, EXTENDED RELEASE;ORAL 204150-002 Mar 4, 2013 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.